Back to Results
First PageMeta Content
Attention-deficit hyperactivity disorder / Daytrana / Medical prescription / Methylphenidate / Transdermal patch / Methadone / Pharmacy / Pharmacology / Chemistry / Pharmaceutical sciences


Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Office of Surveillance and Epidemiology
Add to Reading List

Open Document

File Size: 73,36 KB

Share Result on Facebook

City

Miami / /

Company

IMS Health / D. Drug Use Data / AstraZeneca / Noven Pharms Inc / Epidemiology II Office / /

Country

United States / /

Event

FDA Phase / /

IndustryTerm

outpatient retail pharmacy utilization patterns / outpatient retail pharmacy setting / retail pharmacies / treatment of Attention Deficit Hyperactivity Disorder / outpatient retail pharmacy utilization / non-retail channels / non-retail setting data / retail / age / retail pharmacy dispensing / outpatient retail pharmacy / outpatient retail pharmacies / drug products / outpatient retail pharmacy drug utilization patterns / outpatient retail settings / /

MedicalCondition

ADHD / Other Emotional Child Disorder / Attention Deficit Hyperactivity Disorder / emotional disorders / Attention Deficit Disorder / Infantile Autism / Indications Attention deficit hyperactivity disorder / /

OperatingSystem

OSE / /

Organization

SDI’s PDDA / Pediatric Advisory Committee / Division of Epidemiology / office of Surveillance / office of Pediatric Therapeutics / FDA / office of Surveillance and Epidemiology Subject / obtained using SDI’s PDDA / /

Person

Hina Mehta / Kusum Mistry / /

Position

contractor / Deputy Director / Director / Commissioner / EXECUTIVE / Physician / Analyst / General / Epidemiology.** CONTENTS EXECUTIVE / Associate Director Pediatric and Maternal Health Staff Office / /

Product

Daytrana / Daytrana® (Methylphenidate) / Dosage Form Transdermal Patch / /

ProvinceOrState

Florida / /

SocialTag